Gene · 79679
Papers2,409
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
221 to 240 of 2,409
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Altered Serum Alpha1-Antitrypsin Protease Inhibition before and after Clinical Hematopoietic Stem Cell Transplantation: Association with Risk for Non-Relapse Mortality. | Int J Mol Sci | 2023 | 38203593 | PubTator, text mining | PubMed |
| microRNA-Based Cancer Diagnosis and Therapy. | Int J Mol Sci | 2023 | 38203401 | PubTator, text mining | PubMed |
| CD24 May Serve as an Immunotherapy Target in Triple-Negative Breast Cancer by Regulating the Expression of PD-L1. | Breast Cancer (Dove Med Press) | 2023 | 38164371 | PubTator, text mining | PubMed |
| Targeting the immune microenvironment for ovarian cancer therapy. | Front Immunol | 2023 | 38164130 | PubTator, text mining | PubMed |
| The role of immune checkpoints in antitumor response: a potential antitumor immunotherapy. | Front Immunol | 2023 | 38162657 | PubTator, text mining | PubMed |
| A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors. | Front Immunol | 2023 | 38152397 | PubTator, text mining | PubMed |
| Upper gastrointestinal tract microbiota with oral origin in relation to oesophageal squamous cell carcinoma. | Ann Med | 2023 | 38151037 | PubTator, text mining | PubMed |
| Unlocking molecular mechanisms and identifying druggable targets in matched-paired brain metastasis of breast and lung cancers. | Front Immunol | 2023 | 38149244 | PubTator, text mining | PubMed |
| Alternative immune checkpoints in immunoregulatory profile of cancer stem cells. | Heliyon | 2023 | 38144305 | PubTator, text mining | PubMed |
| Generation and Characterization of SORT1-Targeted Antibody-Drug Conjugate for the Treatment of SORT1-Positive Breast Tumor. | Int J Mol Sci | 2023 | 38139459 | PubTator, text mining | PubMed |
| Molecular Characterization and Establishment of a Prognostic Model Based on Primary Immunodeficiency Features in Association with RNA Modifications in Triple-Negative Breast Cancer. | Genes (Basel) | 2023 | 38136994 | PubTator, text mining | PubMed |
| Emerging Therapeutic Targets and Drug Resistance Mechanisms in Immunotherapy of Hematological Malignancies. | Cancers (Basel) | 2023 | 38136311 | PubTator, text mining | PubMed |
| Exploring the prognostic value of S100A11 and its association with immune infiltration in breast cancer. | Sci Rep | 2023 | 38129538 | PubTator, text mining | PubMed |
| New insights into the correlations between circulating tumor cells and target organ metastasis. | Signal Transduct Target Ther | 2023 | 38129401 | PubTator, text mining | PubMed |
| Microphysiological systems for solid tumor immunotherapy: opportunities and challenges. | Microsyst Nanoeng | 2023 | 38106674 | PubTator, text mining | PubMed |
| Metabolic reprogramming involves in transition of activated/resting CD4+ memory T cells and prognosis of gastric cancer. | Front Immunol | 2023 | 38090588 | PubTator, text mining | PubMed |
| Comprehensive analysis of clinical prognosis and biological significance of CNIH4 in cervical cancer. | Cancer Med | 2023 | 38087815 | PubTator, text mining | PubMed |
| Identification of necroptosis-related lncRNAs for prognosis prediction and screening of potential drugs in patients with colorectal cancer. | World J Gastrointest Oncol | 2023 | 38077636 | PubTator, text mining | PubMed |
| Histone ubiquitination-related gene CUL4B promotes lung adenocarcinoma progression and cisplatin resistance. | Front Genet | 2023 | 38075690 | PubTator, text mining | PubMed |
| [Effect of miR-125b on T Cell Activation in Aplastic Anemia by Targetting B7-H4]. | Zhongguo Shi Yan Xue Ye Xue Za Zhi | 2023 | 38071063 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/79679/papers?page=12